Allogene Therapeutics (ALLO) Revenue (2021 - 2024)

Allogene Therapeutics has disclosed Revenue across 4 years of filings, most recently posting $22000.0 for Q1 2024.

• Revenue for Q1 2024 came in at $22000.0, down 26.67% year-over-year; the trailing twelve-month figure through Dec 2024 was $22000.0 (down 76.84% YoY), and the FY2024 annual result was $22000.0, down 76.84% from the prior year.
• Revenue came in at $22000.0 for Q1 2024 at Allogene Therapeutics, up from $21000.0 in the prior quarter.
• In the past five years, Revenue ranged from a high of $75.7 million in Q4 2021 to a low of $21000.0 in Q4 2023.
• The 4-year median for Revenue is $30000.0 (2023), against an average of $8.8 million.
• Peak annual rise in Revenue reached 45.45% in 2022, while the deepest fall reached 99.97% in 2022.
• Allogene Therapeutics' Revenue stood at $75.7 million in 2021, then tumbled by 99.97% to $26000.0 in 2022, then decreased by 19.23% to $21000.0 in 2023, then grew by 4.76% to $22000.0 in 2024.
• The last three Revenue figures came in at $22000.0 (Q1 2024), $21000.0 (Q4 2023), and $22000.0 (Q3 2023), per Business Quant data.